Haemostasis is the body's finely tuned process of maintaining blood flow while preventing excessive bleeding or clot formation. It operates through a delicate equilibrium of pro-coagulant and anti-coagulant proteins, ensuring that blood remains fluid under normal conditions but can rapidly clot when injury occurs.
1️⃣ Vasoconstriction & Injury Response
- When a blood vessel is injured, local vasoconstriction occurs to minimize blood loss.
- Collagen and tissue factor are exposed, signaling platelets to respond.
2️⃣ Primary Haemostasis: Platelet Plug Formation
- Platelets adhere to exposed von Willebrand factor (vWF), initiating adhesion.
- Activated platelets release ADP and thromboxane A2, triggering further platelet aggregation.
- Platelets form a temporary plug through fibrinogen bridges, stabilizing the site of injury.
- This process kickstarts the coagulation cascade.
3️⃣ Secondary Haemostasis: Coagulation Cascade Activation
- The intrinsic and extrinsic pathways lead to the activation of Factor X, initiating the common pathway.
- Factor X converts prothrombin (Factor II) into thrombin (Factor IIa), a key enzyme in clot formation.
- Thrombin transforms fibrinogen (Factor I) into insoluble fibrin, reinforcing the clot.
- Factor XIII cross-links fibrin strands, stabilizing the clot further.
The Intrinsic vs. Extrinsic Pathways: How Does Clotting Begin?
๐ฉธ Intrinsic Pathway: Triggered when Factor XII contacts negatively charged collagen on damaged endothelium. Platelets release Factor VIII, which combines with Factor IX, ultimately activating Factor X.
๐ฉธ Extrinsic Pathway: Initiated when Factor VII exits circulation following injury. Tissue factor (Factor III) binds Factor VII, activating Factor X.
๐ฌ Key Test Indicators:
- Prothrombin Time (PT) measures the extrinsic pathway.
- Activated Partial Thromboplastin Time (aPTT) assesses intrinsic pathway function.
- D-dimer levels indicate ongoing fibrinolysis, helping assess clot breakdown activity
Fibrinolysis: Clearing Clots Once Healing Begins
Once tissue repair is complete, plasminogen is converted into plasmin, degrading the fibrin clot into soluble fragments.
๐ Tranexamic acid inhibits plasmin formation, reducing excessive bleeding in clinical settings.
D-dimers are protein fragments produced after fibrinolysis – can be used to screen for increased fibrinolytic activity
Clotting Regulators: Preventing Unchecked Thrombosis
Several proteins help regulate haemostasis, preventing excessive clot formation:
✅ Antithrombin – Inhibits thrombin and several clotting factors.
✅ Protein C & Protein S – Work together to degrade Factors Va and VIIIa, slowing clotting.
✅ Tissue Factor Pathway Inhibitor – Inhibits the TF-VIIa complex to prevent excessive Factor X activation.
๐ก Clinical Correlations: When Haemostasis Fails
๐ด Bleeding Disorders:
- Von Willebrand Disease (VWD): Deficiency or dysfunction of vWF leads to prolonged bleeding, commonly affecting mucosal surfaces.
- Haemophilia A & B: Factor VIII or IX deficiencies impair the intrinsic pathway, causing deep tissue and joint bleeding.
๐ฉธ Clotting Disorders:
Assessing Bleeding & Clotting Disorders: Key Questions & Investigations
When evaluating a patient for a bleeding or clotting disorder, a structured approach is crucial. The history provides essential diagnostic clues, while laboratory investigations confirm the underlying pathology.
Key Questions for Bleeding Disorders
1️⃣ Is there evidence of a bleeding problem?
- History of easy bruising, epistaxis, gum bleeding, or prolonged menstrual bleeding?
- Excessive bleeding after surgery, trauma, or dental procedures?
2️⃣ What is the location of bleeding?
- Mucosal bleeding (nose, gums, GI tract)? → Suggests platelet dysfunction or von Willebrand disease.
- Joint or deep tissue bleeding? → Often seen in haemophilia or coagulation factor deficiencies.
3️⃣ What is the timing of bleeding relative to a haemostatic challenge?
- Immediate bleeding post-injury → More likely platelet-related.
- Delayed bleeding (hours to days) → Suggests coagulation factor deficiency (e.g., haemophilia).
4️⃣ Medication history?
- Use of aspirin, NSAIDs, anticoagulants (warfarin, DOACs), or herbal supplements that affect haemostasis?
5️⃣ Family history of bleeding disorders?
- Consider haemophilia, von Willebrand disease, or rare inherited platelet disorders.
Key Investigations for Bleeding Disorders
๐ฌ Basic Tests:
✅ Full Blood Count (FBC) → Assess platelets and haemoglobin.
✅ Peripheral Blood Film → Look for platelet abnormalities or microcytic anaemia (suggestive of chronic blood loss).
✅ Standard Coagulation Screen:
- Activated Partial Thromboplastin Time (aPTT) → Tests intrinsic pathway (Factors VIII, IX, XI, XII).
- Prothrombin Time (PT) → Tests extrinsic pathway (Factors VII, X, V, II, I).
- Thrombin Time (TT) → Assesses fibrinogen function.
- International Normalized Ratio (INR) → Evaluates warfarin therapy or liver dysfunction.
✅ Fibrinogen levels → Identifies fibrinogen deficiency or consumption (e.g., DIC).
๐ฌ Specialty Tests:
✅ Von Willebrand Factor Antigen & Activity Assays → Diagnose VWD.
✅ Platelet Function Assays (PFA-100) → Evaluate platelet dysfunction.
✅ Mixing Studies → Differentiate factor deficiencies from inhibitors (e.g., lupus anticoagulant).
✅ Thrombophilia Workup (if suspect hypercoagulability) → Includes Factor V Leiden, Protein C/S, Antithrombin, Lupus Anticoagulant.
Key Questions for Clotting Disorders
1️⃣ Is there evidence of a clotting problem?
- History of deep vein thrombosis (DVT), pulmonary embolism (PE), or recurrent pregnancy loss?
- Unexplained stroke, myocardial infarction, or organ ischemia at a young age?
2️⃣ What are the risk factors?
- Immobility, malignancy, smoking, or estrogen exposure (OCP, pregnancy)?
- Recent surgery, trauma, or prolonged hospitalization?
3️⃣ Family history of clotting disorders?
- Any relatives with DVT, PE, Factor V Leiden mutation, or other thrombophilia?
4️⃣ Medication history?
- Use of hormonal contraceptives, chemotherapy, or pro-thromb๐ฉธ๐ฉธ๐ฉธ๐ฉธtic medications?
Key Investigations for Clotting Disorders
๐ฌ Basic Tests:
✅ FBC (platelet count) → Elevated platelets may indicate essential thrombocythemia, while low platelets may suggest DIC.
✅ D-dimer → Elevated in active clot formation (DVT/PE screening, DIC assessment).
✅ Standard Coagulation Screen (PT, aPTT, TT, INR) → Helps assess clotting pathway abnormalities.
๐ฌ Thrombophilia Screen (if clinically indicated):
✅ Factor V Leiden mutation → Most common inherited thrombophilia.
✅ Prothrombin Gene Mutation 20210A → Increases thrombotic risk.
✅ Protein C, Protein S, and Antithrombin III levels → Deficiencies lead to increased clotting tendency.
✅ Lupus Anticoagulant & Anticardiolipin Antibodies → Diagnose antiphospholipid syndrome.
✅ Anti-beta 2 Glycoprotein I Antibodies → Supports APS diagnosis.
No comments:
Post a Comment